Marengo Therapeutics

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Marengo Therapeutics
Mar 27, 2025, 18:32 | Blog
We are proud to share that Marengo will be presenting during the Clinical Plenary Oral Session at the upcoming AACR Annual Meeting - Marengo Therapeutics
Marengo Therapeutics shared a post on LinkedIn: "We are proud to share that Marengo will…
Dec 21, 2024, 18:46 | Insight
Marengo Initiated Phase 2 Trial of Invikafusp Alfa for PD-1 Resistant Tumors, Expands to Europe
Marengo Therapeutics, Inc., a clinical-stage biotechnology company focused on precision T cell activation, has announced…
Dec 9, 2024, 13:36 | Blog
Zhen Su: Overcome PD-1 Resistant in Solid Tumor with a Novel Dual T-cell Agonist approach
Zhen Su, CEO at Marengo Therapeutics, shared a post on LinkedIn: "Overcome PD-1 resistant in…
Sep 14, 2024, 12:01 | Blog
Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!
Zhen Su, CEO at Marengo Therapeutics, posted the following on LinkedIn: “Phase III NSCLC Ivonescimab (Anti-VEGF/PD-1…
Apr 12, 2024, 10:14 | Societies
Shiva Bolourchi: Marengo Therapeutics is proud to be disclosing new data at AACR describing the innovative expansion of our portfolio
Ke Liu, Chief Development Officer at Marengo Therapeutics, shared a post by Shiva Bolourchi, Head…
Mar 6, 2024, 10:51 | Blog
Guru Sonpavde: Phase I clinical trial early drug development update from AdventHealth Central Florida
Guru Sonpavde, Medical Director at the AdventHealth Cancer Institute, shared a post on LinkedIn: "Phase I clinical…
All: 6 Posts: 1 - 100
Special Coverage